Second "approvable" letter for the ulcerative colitis therapy issued March 24 indicates that approval of the drug will await the determination of what comparative claims will be allowed in labeling between balsalazide and Procter & Gamble's Asacol (mesalamine), Salix said. FDA also rescinded its approval of the brand name BalAsa March 24, citing potential name confusion with Roberts' Pentasa. Salix plans to respond in April with a submission that will include a new brand name, a formal response to the proposed label, and updated safety data from recently completed balsalazide clinical trials. The agency first deemed the drug approvable June 15, 1998
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth